The word NEWS written in gold on black metal blocks against a sparkly background. Image by enterlinedesign via Shutterstock.
🗞️ Read the February IHI newsletter: link.europa.eu/HfTKq7
🤝 Our director on what makes a good public-private partnership
🚀 An interview with a young researcher on how working in our @imi-amypad.bsky.social project shaped her career
👋 New projects Cities@Heart & PROBE
#HorizonEU #health #research
Today is the International Day of Women and Girls in Science, and we're shining the spotlight on Ariane Bollack, who took part in the AMYPAD project as a PhD student. We asked her how taking part in the PPP shaped her career.
♀️ Today is the #InternationalDayofWomenandGirlsinScience! 🧠 Meet Ariane Bollack, a former PhD student from the AMYPAD project who's now working in industry. We asked her how the PPP shaped her career & what advice she has for young researchers 👉 link.europa.eu/K6GPPp
#WomenInScience #WomenInSTEM
🎓 Meet Alba Martos Sánchez. She is a full-time PhD student at @barcelonabeta.bsky.social, doing some research in the early-stages of #Alzheimer’s disease.
👉 Read more: amypad.eu/news/recent-...
🎉 Congratulations Dr. Sophie Mastenbroek on successfully defending her PhD cum laude yesterday in Amsterdam 🎓
🌟Wishing Sophie continued success in the exciting journey ahead!
www.amsterdamumc.org/en/research/...
🎓 Meet Prithvi Arunachalam. He is a PhD candidate at Amsterdam UMC, where he contributes to research initiatives including AMYPAD and Euro-PAD.
👉 Read more: amypad.eu/news/recent-...
👉 NEW AMYPAD paper presenting the AMYPAD approach to address data acquisition, processing, interpretation and data sharing challenges!
Congratulations to all authors👏
alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
Today, @ihieurope.bsky.social hosted a webinar on regulatory impact. On behalf of AMYPAD, Gill Farrar presented how we succeeded in the Biomarker Qualification Opinion application for our Centiloid work!
#RegulatoryScience #HorizonEurope #ResearchImpact
Meet the speakers: Ralf Herold, Thorsten Vetter, Silvy Da Rocha Dias, Christina Giannakou, Pierpaolo Moscariello and Oriane Blanquie from the EMA, Gill Farrar from GE Healthcare, Pieter Annaert from KU Leuven and BioNotus, and Marco Viceconti and Giorgio Davico from the University of Bologna
🚨 Happening today! Join us at 14:00 for Regulatory impact: what it is & how to achieve it with your IHI project. Hear from EMA regulators & past projects about their experiences, advice & top tips for achieving maximum impact. Don't miss it! 👉 link.europa.eu/vGdQrY
#RegulatoryScience #HorizonEurope
📣New paper out on the role of cerebral amyloid-β in cortical, allocortical and subcortical atrophy in (mostly) cognitively unimpaired individuals from the AMYPAD Prognostic and Natural History Study!
Congratulations to all authors👏
www.sciencedirect.com/science/arti...
Interested to learn how to maximise your project’s regulatory impact? Register for this online event hosted by @ihieurope.bsky.social ⤵️
www.ihi.europa.eu/news-events/...
Gill Farrar will highlight the regulatory value that our AMYPAD Biomarker Qualification Opinion brought to the amyloid PET field
📢 Check out this perspective review, highlighting the advancements brought by blood biomarkers in Alzheimer's disease🧠🩸
doi.org/10.1002/alz....
We were pleased to join an exciting symposium during #EANM25 last week in Barcelona focused on advancing early diagnosis with PET imaging and biomarkers.
Lyduine Collij shared AMYPAD insights and spoke alongside Prof. Dr. Alexander Drzezga and Prof. dr. Silvia Morbelli.
amypad.eu/news/recent-...
📢 NEW paper out in Alzheimer's & Dementia, using data from the AMYPAD Prognostic and Natural History Study!
Congratulations to all authors 👏
alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
🚀 We’re pleased to announce the release of the latest edition of our newsletter, featuring the release of the AMYPAD raw dataset, highlights from the Euro-PAD symposium and new papers!
👉 Read the full newsletter here: mailchi.mp/e602ab237ff7...
📣NEW AMYPAD out!
The genetic data harmonisation manuscript for the AMYPAD consortium is online in Alzheimer's & Dementia!
Authors provide a detailed pipeline for genotype array data QC, imputation, harmonisation, and PRS computation⤵️
doi.org/10.1002/alz....
📣 #AAIC25 is around the corner!
Whether you’ll be on-site in Toronto or joining online, don’t miss the AMYPAD presentations 👇
For more information about the conference, please visit: aaic.alz.org
📢 NEW AMYPAD paper out in European Journal of Neurology assessing the cost-utility of early versus no amyloid-PET in the diagnostic work-up of memory clinic patients after 6 months. @ihieurope.bsky.social
Congratulations to all authors 👏
doi.org/10.1111/ene....
This past two days, we hosted the Euro-PAD symposium to discuss the latest advancements in neuroimaging and biomarkers for #Alzheimer’s disease, as well as to share updates from the Euro-PAD initiative over the past year. ⤵️
www.barcelonabeta.org/en/news/news...
📣Yesterday and today, the Euro-PAD community convened in Barcelona for a scientific symposium hosted by @barcelonabeta.bsky.social.
👉Almost 100 participants gathered to discuss the latest advancements in neuroimaging and biomarkers for Alzheimer’s disease!
amypad.eu/news/recent-...
This morning, before the symposium, we held two parallel workshops, one led by #BBRC researchers focused on fluid biomarkers and the other led by
@acealzheimercenter.com focused on clinical trials
Today and tomorrow we are hosting the EuroPAD 2025 symposium!
#EuroPAD seeks to enhance and extend late-stage biomarker cohorts focused on Alzheimer’s, with the specific aim of establishing the most extensive and deeply phenotyped longitudinal cohort of at-risk individuals.
📢 JUST PUBLISHED: Paper in @natrevdrugdiscov.nature.com on how to maximise #RegulatoryImpact from public-private partnerships, co-authored by IHI’s Nathalie Seigneuret. Check out 3 examples to follow from C-Path & @imi-amypad.bsky.social
👇 Read it below 👇
#IHITransformingHealth #RegulatoryScience
📣New paper out highlighting lessons learned that could help maximise the regulatory impact of consortium-based projects.
C-Path and AMYPAD are featured as examples of projects that have achieved regulatory successes
👉https://www.nature.com/articles/d41573-025-00098-8
NEW paper out entitled "Quantification of baseline amyloid PET in individuals with subjective cognitive decline can identify risk of amyloid accumulation and cognitive worsening: the FACEHBI study"
Congratulations to all authors 👏
Check it out now⤵️
link.springer.com/article/10.1...
📢Exciting news! We're pleased to announce that the AMYPAD raw dataset is now available for data access requests on the Alzheimer's Disease Data Initiative's Workbench!
➡️ Visit the AMYPAD website for more information: amypad.eu/data/
👉Leo Pieperhoff presented findings from the AMYPAD PHNS study at #ADPD2025 today!
The harmonised data are available on the #ADWorkbench of the Alzheimer’s Disease Data Initiative. Interested to learn more? Visit Booth 16 of the Alzheimer’s Disease Data Initiative at #ADPD2025!
🧠 #ADPD2025 DAY 2!
Join us in Room Hall F2 today at 13:50 for the symposium “WHITE MATTER ALTERATIONS”.
Leonard Pieperhoff will be presenting AMYPAD results “Grey/White Matter Contrast Alterations Precede Amyloid Positivity and Atrophy Markers.”
Don’t miss his insightful presentation 🙌
🚨#ADPD2025 is officially underway!
This morning Mario Tranfa, Luigi Lorenzini and Emma Luckett presented data from the AMYPAD, EPAD and Euro-PAD consortiums!
Natàlia Vilor Tejedor also presented the #ADWorkbench at the session hosted by the Alzheimer's Disease Data Initiative!
✨ Today marks the start of #ADPD2025 in Vienna!
If you're attending the conference, don’t miss the AMYPAD, EPAD and EUROPAD-related talks.
We hope to see you there to catch up on our latest advancements 🙌
👉 Earlier today, we were pleased to present insights from the AMYPAD project at #ECCN2025 during a satellite symposium, sponsored by Life Molecular Imaging!
Thanks to everyone who joined us and contributed to the discussion ☺️